Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Endocrine 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 352pembrolizumab 327Pemetrexed 250Cisplatin 222Paclitaxel 149Nivolumab 139durvalumab 134osimertinib 112Docetaxel 112atezolizumab 109Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
EC regimen × Thoracic × 1 year × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Shanghai Henlius Biotech

Phase 3 Active not recruiting
200 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting
203 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡